We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • Stock information
    • Governance
    • Documentation

Our products & pipeline

Our research has initially focused on gene therapy solutions for severe inherited retinal diseases. In the longer term, we hope to find solutions for patients faced with neurodegenerative diseases more generally.
Direct access
  • Diseases we target
  • Leber's Hereditary Optic Neuropathy
  • Retinitis pigmentosa (RP)
  • Geographic atrophy in dry AMD
  • Home >
  • Our products & pipeline

 

 

  • Diseases we target
  • GS010 for LHON
  • GS030 for Retinitis Pigmentosa
  • GS030 for Geographic Atrophy in Dry-AMD

Stay informed

Subscribe to the newsletter to get the latest GenSight Biologics news

Fields marked with an * are required
© 2018 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page